Management of Stable Angina with Nitroglycerin and Ranolazine
Introduction to Stable Angina Management
- The European Society of Cardiology recommends nitroglycerin for immediate symptom relief and situational prophylaxis in all patients with stable angina, while ranolazine is reserved as add-on therapy for patients with persistent symptoms despite optimal first-line treatment 1, 2
Nitroglycerin Therapy
- Short-acting nitroglycerin is mandatory for all stable angina patients, serving as immediate relief of acute anginal episodes and prophylactic use before activities known to trigger angina, as recommended by the European Society of Cardiology with a Class I, Level B recommendation 1
Ranolazine as Add-On Therapy
- Ranolazine should only be added when angina persists despite optimized first-line therapy, with a Class IIa, Level B recommendation from the European Society of Cardiology 1, 2
- Ranolazine provides modest symptomatic benefit in properly selected patients, but does not reduce mortality, myocardial infarction, or need for revascularization, as noted by the European Society of Cardiology 4, 2, 3
Unique Advantages of Ranolazine
- Ranolazine has a neutral hemodynamic profile, making it valuable in patients with bradycardia, hypotension, or diabetes and angina, as recommended by the European Society of Cardiology 4, 2, 5
Contraindications and Precautions
- Ranolazine is absolutely contraindicated in hepatic impairment or liver cirrhosis due to dose-dependent QTc prolongation and increased arrhythmia risk, as warned by the European Society of Cardiology 4, 2, 3
Important Drug Interactions
- Ranolazine increases digoxin concentrations, requiring cautious use if co-administered, and strong CYP3A inhibitors should be avoided, as advised by the European Society of Cardiology 4, 2, 3
Dosing and Administration
- Ranolazine should be started at 500 mg twice daily, escalating to 1000 mg twice daily as needed and tolerated, with a maximum dose recommended by the European Society of Cardiology 2